中慧生物-B(02627.HK)：四价流感病毒亚单位疫苗的上市申请获国家药监局批准

Core Viewpoint - Zhonghui Biotech-B (02627.HK) has received approval from the National Medical Products Administration of China for its quadrivalent influenza virus subunit vaccine aimed at the population aged 6 to 35 months, marking it as the first and only approved vaccine of its kind in China for the entire population and all dosage levels [1] Group 1 - The vaccine represents a significant upgrade over traditional virus split vaccines, offering comprehensive protection, high purity of antigen components, and a lower risk of adverse reactions [1]